Kwon Soon Hyo, Lerman Lilach O
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN; and Division of Nephrology, Soonchunhyang University Hospital, Seoul, Korea.
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN; and Division of Nephrology, Soonchunhyang University Hospital, Seoul, Korea.
Adv Chronic Kidney Dis. 2015 May;22(3):224-31. doi: 10.1053/j.ackd.2014.10.004.
Atherosclerotic renal artery stenosis (ARAS) remains a major cause of secondary hypertension and kidney failure. Randomized prospective trials show that medical treatment should constitute the main therapeutic approach in ARAS. Regardless of intensive treatment and adequate blood pressure control, however, renal and extrarenal complications are not uncommon. Yet, the precise mechanisms, accurate detection, and optimal treatment in ARAS remain elusive. Strategies oriented to early detection and targeting these pathogenic pathways might prevent development of clinical end points. Here, we review the results of recent clinical trials, current understanding of the pathogenic mechanisms, novel imaging techniques to assess kidney damage in ARAS, and treatment options.
动脉粥样硬化性肾动脉狭窄(ARAS)仍然是继发性高血压和肾衰竭的主要原因。随机前瞻性试验表明,药物治疗应成为ARAS的主要治疗方法。然而,尽管进行了强化治疗并实现了血压的充分控制,但肾脏和肾外并发症并不少见。然而,ARAS的确切机制、准确检测和最佳治疗方法仍然难以捉摸。针对早期检测和靶向这些致病途径的策略可能会预防临床终点的出现。在此,我们综述了近期临床试验的结果、对致病机制的当前认识、评估ARAS肾损伤的新型成像技术以及治疗选择。